What is the share price of Sakar Healthcare Ltd (SAKAR) today?
The share price of SAKAR as on 28th July 2026 is ₹839.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sakar Healthcare Ltd (SAKAR) share?
The past returns of Sakar Healthcare Ltd (SAKAR) share are- Past 1 week: -4.72%
- Past 1 month: 2.02%
- Past 3 months: 32.53%
- Past 6 months: 119.84%
- Past 1 year: 135.16%
- Past 3 years: 217.83%
- Past 5 years: 360.34%
What are the peers or stocks similar to Sakar Healthcare Ltd (SAKAR)?
The peers or stocks similar to Sakar Healthcare Ltd (SAKAR) include:What is the market cap of Sakar Healthcare Ltd (SAKAR) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sakar Healthcare Ltd (SAKAR) is ₹1821.84 Cr as of 28th July 2026.What is the 52 week high and low of Sakar Healthcare Ltd (SAKAR) share?
The 52-week high of Sakar Healthcare Ltd (SAKAR) is ₹960 and the 52-week low is ₹311.What is the PE and PB ratio of Sakar Healthcare Ltd (SAKAR) stock?
The P/E (price-to-earnings) ratio of Sakar Healthcare Ltd (SAKAR) is 59.77. The P/B (price-to-book) ratio is 6.38.Which sector does Sakar Healthcare Ltd (SAKAR) belong to?
Sakar Healthcare Ltd (SAKAR) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sakar Healthcare Ltd (SAKAR) shares?
You can directly buy Sakar Healthcare Ltd (SAKAR) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sakar Healthcare Ltd
SAKAR Share Price
NSE₹839.901.19% (+9.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SAKAR Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SAKAR Performance & Key Metrics
SAKAR Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 50.45 | 6.38 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.27 | 5.97 | 0.52% |
100%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
SAKAR Company Profile
Sakar Healthcare ltd. is engaged in providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Liquid Injectables in ampoules and vials, and Dry Powder Injections.
SUNPHARMA
PE Ratio
41.25
41.25
1Y Return
15.95%
15.95%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
88.25
88.25
1Y Return
38.55%
38.55%
Buy Reco %
78.57
78.57
CIPLA
PE Ratio
29.35
29.35
1Y Return
10.34%
10.34%
Buy Reco %
63.89
63.89
ZYDUSLIFE
PE Ratio
21.93
21.93
1Y Return
13.07%
13.07%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.66
20.66
1Y Return
22.93%
22.93%
Buy Reco %
55.56
55.56
SAKAR Forecast
SAKAR Forecasts
Price
Revenue
Earnings
SAKAR Share Price Forecast
SAKAR Share Price Forecast
2026
Current
₹830.00
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹830.00
Baseline
Forecast for Jul 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SAKAR Company Revenue Forecast
SAKAR Company Revenue Forecast
2026
Current
₹254.02
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2026
Current
₹254.02
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
SAKAR Stock EPS (Earnings Per Share) Forecast
SAKAR Stock EPS (Earnings Per Share) Forecast
2026
Current
₹13.70
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹13.70
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SAKAR
SAKAR
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SAKAR Income Statement
SAKAR Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 43.83 | 41.61 | 43.15 | 43.71 | 50.42 | 53.13 | 58.78 | 70.85 | 71.27 | 74.52 | ||||||||||
Operating & Other expenses | 32.09 | 30.45 | 31.28 | 31.71 | 34.52 | 40.03 | 46.21 | 51.75 | 44.86 | 51.72 | ||||||||||
EBITDA | 11.74 | 11.16 | 11.87 | 12.00 | 15.90 | 13.10 | 12.57 | 19.10 | 26.41 | 22.80 | ||||||||||
| Depreciation/Amortization | 4.87 | 5.06 | 5.12 | 5.23 | 5.48 | 5.57 | 5.68 | 6.37 | 5.94 | 6.54 | ||||||||||
| PBIT | 6.87 | 6.10 | 6.75 | 6.77 | 10.42 | 7.53 | 6.89 | 12.73 | 20.47 | 16.26 | ||||||||||
| Interest & Other Items | 2.08 | 1.40 | 1.64 | 1.30 | 4.19 | 2.14 | 1.53 | 1.78 | 2.41 | 1.67 | ||||||||||
| PBT | 4.79 | 4.70 | 5.11 | 5.47 | 6.23 | 5.39 | 5.36 | 10.95 | 18.06 | 14.59 | ||||||||||
| Taxes & Other Items | 1.67 | 2.29 | 0.31 | 0.94 | 0.48 | 0.71 | 0.82 | 0.70 | 7.04 | 4.29 | ||||||||||
| Net Income | 3.12 | 2.41 | 4.80 | 4.53 | 5.75 | 4.68 | 4.54 | 10.25 | 11.02 | 10.30 | ||||||||||
| EPS | 1.46 | 1.10 | 2.17 | 2.08 | 2.66 | 2.11 | 2.03 | 4.59 | 4.96 | 4.62 |
SAKAR Company Updates
FY 2026FY 2026
Investor Presentation
May 13PDF
Feb 10PDF
FY 2025FY 2025
FY 2024FY 2024
FY 2023FY 2023
Investor Presentation
Oct 8PDF
FY 2022FY 2022
FY 2021FY 2021
FY 2020FY 2020
FY 2019FY 2019
Investor Presentation
Dec 12PDF
SAKAR Stock Peers
SAKAR Past Performance & Peer Comparison
SAKAR Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sakar Healthcare Ltd | 59.77 | 6.38 | — |
| Sun Pharmaceutical Industries Ltd | 41.25 | 5.65 | 0.81% |
| Torrent Pharmaceuticals Ltd | 88.25 | 10.86 | 0.67% |
| Cipla Ltd | 29.35 | 3.30 | 0.92% |
SAKAR Stock Price Comparison
Compare SAKAR with any stock or ETFCompare SAKAR with any stock or ETF
SAKAR
SAKAR Holdings
SAKAR Shareholdings
SAKAR Promoter Holdings Trend
SAKAR Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SAKAR Institutional Holdings Trend
SAKAR Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 3.57%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SAKAR Shareholding Pattern
SAKAR Shareholding Pattern
SAKAR Shareholding History
SAKAR Shareholding History
Foreign Institutions
smallcases containing SAKAR stock
smallcases containing SAKAR stock
Looks like this stock is not in any smallcase yet.
SAKAR Events
SAKAR Events
SAKAR Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SAKAR has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SAKAR Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SAKAR has not given any dividends in last 5 years
SAKAR Dividends
SAKAR Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSAKAR Stock News & Opinions
SAKAR Stock News & Opinions
Articles & Videos
Corporate
Corporate
Sakar Healthcare to hold AGMSakar Healthcare announced that the 22th Annual General Meeting(AGM) of the company will be held on 22 September 2026.
2 days agoCapital Market - Live
Earnings
Earnings
Sakar Healthcare consolidated net profit rises 120.13% in the June 2026 quarterNet profit of Sakar Healthcare rose 120.13% to Rs 10.28 crore in the quarter ended June 2026 as against Rs 4.67 crore during the previous quarter ended June 2025. Sales rose 38.36% to Rs 72.97 crore in the quarter ended June 2026 as against Rs 52.74 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales72.9752.74 38 OPM %29.1224.10 - PBDT21.1210.96 93 PBT14.585.38 171 NP10.284.67 120 Powered by Capital Market - Live
3 days agoCapital Market - Live
Corporate
Corporate
Sakar Healthcare announces board meeting dateSakar Healthcare will hold a meeting of the Board of Directors of the Company on 24 July 2026.
1 week agoCapital Market - Live
Spotlight
Spotlight
Sakar Healthcare jumps after Gautam Baid-founded fund buys stake via bulk dealAccording to the bulk deal data on the NSE , Stellar Wealth Partners India Fund I LP purchased 1.95 lakh shares, representing a 0.88% equity stake, at an average price of Rs 664.58 per share. Gautam Baid or Stellar Wealth Partners India Fund I LP did not feature in Sakar Healthcare's shareholding pattern for the quarter ended 31 March 2026. This suggests a fresh stake entry in the current quarter. Stellar Wealth Partners India Fund I LP is a Delaware-based investment partnership founded by investor Gautam Baid. Ahmedabad-based Sakar Healthcare is a pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products. On a consolidated basis, Sakar Healthcare's net profit surged 91.32% to Rs 11.02 crore while net sales rose 41.52% to Rs 71.10 crore in Q4 March 2026 over Q4 March 2025. Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Earnings
Sakar Healthcare consolidated net profit rises 91.32% in the March 2026 quarterNet profit of Sakar Healthcare rose 91.32% to Rs 11.02 crore in the quarter ended March 2026 as against Rs 5.76 crore during the previous quarter ended March 2025. Sales rose 41.52% to Rs 71.10 crore in the quarter ended March 2026 as against Rs 50.24 crore during the previous quarter ended March 2025. For the full year,net profit rose 74.17% to Rs 30.48 crore in the year ended March 2026 as against Rs 17.50 crore during the previous year ended March 2025. Sales rose 41.76% to Rs 251.74 crore in the year ended March 2026 as against Rs 177.58 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales71.1050.24 42 251.74177.58 42 OPM %36.9131.31 -27.3727.98 - PBDT24.0011.71 105 63.3242.46 49 PBT18.066.24 189 39.7621.58 84 NP11.025.76 91 30.4817.50 74 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Sakar Healthcare to hold board meetingSakar Healthcare will hold a meeting of the Board of Directors of the Company on 12 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Sakar Healthcare consolidated net profit rises 126.27% in the December 2025 quarterNet profit of Sakar Healthcare rose 126.27% to Rs 10.25 crore in the quarter ended December 2025 as against Rs 4.53 crore during the previous quarter ended December 2024. Sales rose 62.00% to Rs 70.34 crore in the quarter ended December 2025 as against Rs 43.42 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales70.3443.42 62 OPM %26.4327.06 - PBDT17.3310.76 61 PBT10.955.53 98 NP10.254.53 126 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Sakar Healthcare to conduct board meetingSakar Healthcare will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Sakar Healthcare consolidated net profit declines 5.42% in the September 2025 quarterNet profit of Sakar Healthcare declined 5.42% to Rs 4.54 crore in the quarter ended September 2025 as against Rs 4.80 crore during the previous quarter ended September 2024. Sales rose 34.55% to Rs 57.56 crore in the quarter ended September 2025 as against Rs 42.78 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales57.5642.78 35 OPM %19.7426.88 - PBDT11.0410.23 8 PBT5.365.11 5 NP4.544.80 -5 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Sakar Healthcare to convene board meetingSakar Healthcare will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 21.5%, vs industry avg of 12.48%
Over the last 5 years, market share increased from 0.03% to 0.05%
Over the last 5 years, net income has grown at a yearly rate of 23.31%, vs industry avg of 10.55%